Clinical trials
Trop2 clinical trials
Below are recruiting trop2 clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07471776RecruitingPhase 2
Predicting ADC treatment response with PET scans in advanced breast cancer
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07151898Recruiting
PET/CT scan to see if a new drug is working in advanced lung cancer
This trial tests whether a special PET/CT scan can show how well a Trop2-targeting drug is working in people with advanced lung cancer that has already been treated. It aims to improve how we monitor treatment response.
Xiamen, FujianAges 18 years+ - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT07046689Recruiting
PET scans to check Trop2 ADC treatment in breast cancer
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
Xiamen, FujianAges 18 years+ - NCT07046702Recruiting
PET scan using a new tracer for solid tumors
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
Xiamen, FujianAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06104085Recruiting
Imaging test for Trop2 in triple-negative breast cancer
This trial tests a new imaging agent (99mTc-MY6349) to see if it can detect Trop2, a protein found on some breast cancer cells. It may help doctors better see and understand triple-negative breast cancer that has spread.
Beijing, Beijing MunicipalityAges 18–80 - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06851663RecruitingPhase 2/Phase 3
New PET scan for many solid tumors
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
ShanghaiAges 18–75 - NCT06972771Recruiting
Trop2-imaging dye helps find early bladder cancer during surgery
This study uses a special imaging dye that targets a protein called Trop2, which is often found on bladder cancer cells. During your surgery, the dye will help doctors see the cancer more clearly with advanced imaging so they can remove it completely.
Kunming, YunnanAges 18–80 - NCT07251868Recruiting
Study of SG in breast cancer with brain metastases
This study follows patients with breast cancer that has spread to the brain and who have already received the drug Sacituzumab Govitecan (SG). The goal is to learn how well SG works in real-world settings and to see how patients are doing over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Chandler, ArizonaAges 18 years+ - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT07610616Recruiting
Testing ADC Drug Effectiveness Using Lung Cancer Lab Models
This research study tests how a lung cancer drug called Trastuzumab deruxtecan (T-DXd) works by growing your cancer cells in a lab dish and studying them with your immune cells. The goal is to better understand which patients might benefit most from this treatment.
Guangzhou, GuangdongAges 18–100
Hear when a new Trop2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for trop2?
- Yes. Clin2 currently lists 18 recruiting trop2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a trop2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a trop2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.